THE SCIENCE OF IGY TECHNOLOGY
IgY technology is a fast spreading field in the life sciences. The scientific community has long known the potential of IgY antibodies. If you run a search in the National Institutes of Health’s (NIH’s) National Library of Medicine, PubMed.gov, a search for IgY will lead to over 1300 search results. A review of these studies will demonstrate IgY antibody’s ability to prevent or cure disease in humans and in animals. In addition, IgY antibodies have demonstrated potential for applications in diagnostic tests or protein purification processes.
There are two types of IgY Antibodies: Specific and Non-Specific.
Specific IgY Antibodies
IgY antibodies can be created to target specific antigens, which are toxins or other foreign substances. Antigens can be complex antigens from viruses, bacteria or parasites or single antigens from proteins, polysaccharides, peptides, and nucleic acids. For example, IgY antibodies can minimize the resistance seen with the use of antibiotic use to treat bacterial infections since the IgY antibodies are directed to specific and usually multiple antigens on the bacteria, which require multiple genes for their synthesis and it is, therefore, difficult for the bacteria to mutate to become resistant to the IgY antibodies.
IgY antibodies created to target specific antigens are intended to have a localized, highly target-specific, predictable, and efficient antigen-antibody interaction. The proposed mechanisms of action for these IgY antibodies are:
Inhibition of bacterial and viral adhesion to host cell surface
Suppression of bacterial colonization and viral cell-to-cell spread
Bacterial agglutination resulting in microbial immobilization and being flushed out of the body
Inhibition of enzyme activity
Neutralization of toxin activity
When compared to vaccines, passive immunotherapy using specific IgY has distinct advantages including:
Immediate and local onset of action
High antibody-antigen affinity
Applicability to a broader range of patients from infants to adults and immunodeficient/immunocompromised patients
It is non-toxic and is generally regarded as safe (GRAS)
Some advantages of specific IgY relative to antibiotics include:
It is natural
It is safe without toxic tissue residues
It avoids environmental contamination with synthetic chemical drugs
It does not induce specific pathogenic microorganism resistance since it is directed to multi-antigenic targets which need multiple genes for their synthesis
It is highly specific in its reactivity and controls only targeted pathogens without affecting normal bacterial flora
It does not induce adverse side effects unlike synthetic drugs
Specific IgY antibodies have also been used to diagnose viral, bacterial, parasitic infections as well as cancers through their targeting of specific antigens.
Non-specific or Natural IgY Antibodies
Non-specific IgY antibodies, or natural IgY, are purified IgY which have been spray dried but have not been otherwise altered provide support for the digestive tract removing relevant pathogens, supports immune health and the body’s natural defenses.
Muno-IgY is our proprietary non-specific antibody solution. We developed Muno-IgY to enhance the human body’s natural immune system through direct supplementation of antibodies. Muno-IgY is a premium, yet cost-effective, concentrated source of immunoglobulins which have been isolated and purified using IGY Immune Technologies & Life Sciences patented proprietary processes.
Muno-IgY is available in a general form ideal as daily supplements and as a functional food ingredient for branded foods and drinks.
The Potential is Limitless
There are a large number of publications that provide an overview of IgY Technology and potential applications. Here are our recommendations. (Links will open new windows).
Egg Yolk Antibodies (IgY) and Their Applications in Human and Veterinary Health: A Review
Pereira, Tilburg, Florean, and Guedes. Int Immunopharmacol. 2019 Aug; 73: 293-30
Use of IgY Antibodies in Human and Veterinary Medicine
Rudiger Schade, Xiao-Uing Zhang and Horacio Raul Terzolo. Bioactive Egg Compounds (ed. by Rainer Huopalahti, Rosina López-Fandino, Marc Anton and Rüdiger Schade) @ Springer-Verlag Berlin Heidelberg 2007
Oral passive IgY-based immunotherapeutics
Rahman, Nguyan, Icatlo Jr, Umeda, Kodama. Human Vaccines & Immunotherapeutics. May 2013. 1039-1048.
IgY-technology (egg yolk antibodies) in human medicine: A review of patents and clinical trials
Leiva, Gallardo, Casanova, Terzolo, Chacana. International Immunopharmacology. 81. 2020 106269
IgY antibodies for the immunoprophylaxis and therapy of respiratory infections
Abbas, El-Kafrawy, Sohrab, Azhar. Human Vaccines & Immunotherapeutics. 2019, Vol 15, No. 1, 264-275.
There are currently over 1,300 additional studies published on PubMed that are focused on the benefits of IgY Technology.
Click here to learn more.